TY - JOUR
T1 - Efficacy of continuous positive airway pressure (CPAP) preventing type 2 diabetes mellitus in patients with obstructive sleep apnea hypopnea syndrome (OSAHS) and insulin resistance
T2 - a systematic review and meta-analysis
AU - Abud, Romina
AU - Salgueiro, Maitte
AU - Drake, Lauren
AU - Reyes, Tomas
AU - Jorquera, Jorge
AU - Labarca, Gonzalo
N1 - Publisher Copyright:
© 2019 Elsevier B.V.
PY - 2019/10
Y1 - 2019/10
N2 - Background: Obstructive sleep apnea/hypopnea syndrome (OSAHS) is a very common, yet undiagnosed, breathing disorder that has many more implications besides disrupted sleep. Its role as an independent risk factor for metabolic abnormalities such as insulin resistance (IR) and impaired glucose tolerance is becoming increasingly recognized. The main treatment for OSAHS is continuous positive airway pressure (CPAP), however the impact of CPAP on IR and glucose metabolism is still debated. Objectives: Compile all available evidence regarding the effect of CPAP on IR in non-diabetic OSA patients. Methods: A literature search in Medline, Epistemonikos and the Cochrane Controlled Trial Register were searched through March 2018. We included Randomized Controlled Trials (RCTs) comparing CPAP treatment with sham CPAP, placebo or no treatment in non-diabetic adults with OSAHS. Risk of Bias was evaluated using Cochrane tool and a meta-analysis evaluating the efficacy of CPAP in both HOMA index and fasting glucose was done. Certain of evidence was rated using GRADE approach. Results: Nine studies consisting of 443 participants were included. CPAP treatment significantly improved HOMA index (Mean difference = −0.39 Ui (CI, −0.69 to −0.08), p < 0.05. I2 = 57% (GRADE = LOW). However, CPAP showed no significant changes in fasting glucose (GRADE = LOW). Conclusion: This systematic review and meta-analysis shows evidence that metabolic disturbances could be halted and regressed with CPAP treatment in patients with insulin resistance and OSAHS. In conclusion, treatment with CPAP could improve HOMA IR index.
AB - Background: Obstructive sleep apnea/hypopnea syndrome (OSAHS) is a very common, yet undiagnosed, breathing disorder that has many more implications besides disrupted sleep. Its role as an independent risk factor for metabolic abnormalities such as insulin resistance (IR) and impaired glucose tolerance is becoming increasingly recognized. The main treatment for OSAHS is continuous positive airway pressure (CPAP), however the impact of CPAP on IR and glucose metabolism is still debated. Objectives: Compile all available evidence regarding the effect of CPAP on IR in non-diabetic OSA patients. Methods: A literature search in Medline, Epistemonikos and the Cochrane Controlled Trial Register were searched through March 2018. We included Randomized Controlled Trials (RCTs) comparing CPAP treatment with sham CPAP, placebo or no treatment in non-diabetic adults with OSAHS. Risk of Bias was evaluated using Cochrane tool and a meta-analysis evaluating the efficacy of CPAP in both HOMA index and fasting glucose was done. Certain of evidence was rated using GRADE approach. Results: Nine studies consisting of 443 participants were included. CPAP treatment significantly improved HOMA index (Mean difference = −0.39 Ui (CI, −0.69 to −0.08), p < 0.05. I2 = 57% (GRADE = LOW). However, CPAP showed no significant changes in fasting glucose (GRADE = LOW). Conclusion: This systematic review and meta-analysis shows evidence that metabolic disturbances could be halted and regressed with CPAP treatment in patients with insulin resistance and OSAHS. In conclusion, treatment with CPAP could improve HOMA IR index.
KW - Continuous positive airway pressure
KW - Glucose impairment
KW - Insulin resistance
KW - Obstructive sleep apnea
UR - http://www.scopus.com/inward/record.url?scp=85070229724&partnerID=8YFLogxK
U2 - 10.1016/j.sleep.2018.12.017
DO - 10.1016/j.sleep.2018.12.017
M3 - Article
C2 - 31518943
AN - SCOPUS:85070229724
SN - 1389-9457
VL - 62
SP - 14
EP - 21
JO - Sleep Medicine
JF - Sleep Medicine
ER -